文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

熊去氧胆酸预防腹腔镜袖状胃切除术后胆结石的前瞻性对照研究

Ursodeoxycholic acid for the prevention of gall stones after laparoscopic sleeve gastrectomy: a prospective controlled study.
PubMed 文献 · Surg Endosc · 2022-01-12

该前瞻性对照研究纳入332例拟行LSG的患者,随机分为UDCA组(每日500mg,共12个月)和对照组。术后1年UDCA组胆结石发生率8.5%显著低于对照组32.0%(p<0.001),胆囊切除率由7.0%降至2.3%(p=0.072)。高BMI、血脂异常及未用UDCA是与结石形成独立相关的因素。

要点

  • LSG术后每日UDCA 500mg共12个月,1年胆结石发生率8.5% vs 32.0%(p<0.001)。
  • 胆囊切除指征UDCA组2.3% vs 对照组7.0%(p=0.072),差异无统计学意义。
  • 高BMI、血脂异常及缺乏UDCA预防是结石形成的独立相关因素。

核心结论

  • LSG术后每日UDCA 500mg共12个月能有效减少1年胆结石形成。
  • UDCA使胆囊切除频率从7%降至2.3%。
  • 高BMI和血脂异常是与结石形成独立相关的术前因素。

研究设计与样本

  • 前瞻性对照研究,纳入332例拟行LSG的患者,随机分为UDCA组(每日500mg,共12个月)和对照组(无治疗)。
  • 术后6和12个月行超声检查检测胆结石,复杂胆石症行胆囊切除。

主要发现

  • 术后第一年UDCA组11例(8.5%) vs 对照组41例(32.0%)发生胆结石(p<0.001)。
  • UDCA组3例(2.3%) vs 对照组9例(7.0%)有胆囊切除指征(p=0.072)。
  • 多因素分析显示较高BMI、血脂异常及缺乏UDCA预防是与结石形成独立显著相关的因素。
  • 结石形成与术后6和12个月较高的体重减轻相关。

关键数值与推荐

  • UDCA用法:500mg每日一次,持续12个月。
  • 胆结石发生率UDCA组8.5% vs 对照组32.0%(p<0.001)。
  • 胆囊切除率UDCA组2.3% vs 对照组7.0%(p=0.072)。

临床怎么用

  • LSG术后可考虑每日500mg UDCA共12个月以降低1年胆结石形成风险。
  • 高BMI和血脂异常患者术后结石风险较高,可依据原文独立相关因素进行识别。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity is a risk factor for cholelithiasis. Besides, rapid weight loss after bariatric surgery upsurges the rate of cholelithiasis and acute cholecystitis. This study aimed to compare gallstone development frequency after LSG under ursodeoxycholic acid (UDCA) prophylaxis. METHODS: This prospective controlled study included 332 patients scheduled for LSG randomized to receive 500 mg UDCA daily for 12 months (UDCA Group) or no treatment (Control Group). Ultrasonography was done 6 and 12 months after surgery to detect gallstones. Cholecystectomy was done for complicated cases of cholelithiasis. RESULTS: Seventy-one patients were lost to follow-up, and 3 developed severe adverse effects of UDCA and excluded. Data are presented for 130 patients in the UDCA group and 128 in the Control group. Collectively, 11 patients (8.5%) of the UDCA group and 41 (32.0%) of the Control group developed gall stones during the first postoperative year (p < 0.001). Cholecystectomy was indicated in 3 patients (2.3%) of the UDCA group and 9 (7.0%) of the Control group (p = 0.072). On multivariate analysis, higher BMI, dyslipidemia, and lacking UDCA prophylaxis were the independent factors significantly associated with stone development. Also, stone development was associated with higher weight loss after 6 and 12 months. CONCLUSION: UDCA 500 mg once daily for 12 months after LSG is effective in reducing gallstone formation at 1 year. UDCA administration reduced the frequency of cholecystectomies from 7 to 2.3%. High BMI and dyslipidemia are the independent preoperative factors significantly associated with stone development.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Salman MA, Salman A, Mohamed US, et al. Ursodeoxycholic acid for the prevention of gall stones after laparoscopic sleeve gastrectomy: a prospective controlled study. Surg Endosc. 2022. PMID: 35020052. doi:10.1007/s00464-021-08980-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。